p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin

Lee, Yoke-Sun; Meng, Teh

doi:10.1002/1097-0142(19940501)73:9<2317::aid-cncr2820730913>3.0.co;2-0

Cited by 57 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mutant p53 protein, on the other hand, is generally stable with a longer half-life (1.5-7 hr), and thus its accumulation can be detected. Increases of p53 protein in squamous cell carcinoma and VC have been reported [14], suggesting that mutant p53 gene products may be a prognostic indicator of malignancy [22]. In this study, most cases in both VC and SP were positive for the histone H3 mRNA signal.…”

Section: Figs 2supporting

confidence: 56%

Aberrant Expression Patterns of Histone H3 mRNA, p53, Cyclin D1, and Cyclin B1 in Oral Neoplastic Epithelial Lesions

Nishikawa

Hara

Itô

et al. 2005

Acta Histochem. Cytochem

View full text Add to dashboard Cite

In this paper, tumor growth was studied using oncogenic and kinetic analysis. In verrucous carcinoma (VC, n=22), squamous papilloma (SP, n=18), and hyperkeratotic lesion (HK, n=12), cellular proliferative potentials were evaluated and compared. Co-expression of histone H3 mRNA and p53 protein was not found in HK. In 6 cases (33.3%) of SP, co-expression was detected within the basal and parabasal layers. However, in 17 cases (77.2%) of VC, co-expression of histone H3 mRNA and p53 protein was found extensively from basal to spinous layers. Cyclin D1 was detected in 5 cases (41.7%) of HK and in 14 cases (77.8%) of SP at parabasal layer. While in 20 cases (90.9%) of VC, cyclin D1 was detected from basal to spinous layers, and positive (2+ and 3+) cases (45.4%) increased.Cyclin B1 was detected in 9 cases (75.0%) of HK and in 16 cases (88.9%) of SP at basal or parabasal layer, and in all 22 cases of VC from basal to spinous layers, and positive (2+ and 3+) cases (68.1%) increased. In the intra-cellular distribution of cyclin B1, there were many cases of cytoplasmic types (66.7%) in HK, of cytoplasmic dominant types (50.0%) in SP, and of cytoplasmic dominant types (72.7%) in VC. There were also some cases of nuclear dominant types (27.3%) in VC. The present study suggests that increase of p53 protein, increase of cell proliferation, wide epithelial distribution of cyclins D1 and B1, and increase of positive cells in the nucleus with cyclin B1 were indicators of malignant potential.

show abstract

Section: Figs 2supporting

confidence: 56%

Aberrant Expression Patterns of Histone H3 mRNA, p53, Cyclin D1, and Cyclin B1 in Oral Neoplastic Epithelial Lesions

Nishikawa

Hara

Itô

et al. 2005

Acta Histochem. Cytochem

View full text Add to dashboard Cite

show abstract

“…The accumulation of nuclear p53 found in hyperplastic parathyroid glands could be a physiological and reactive response of native p53 in actively proliferating cells (28)(29)(30)(31). The presence of p53 protein has previously been described in 22% of primary parathyroid hyperplasias (12).…”

Section: Discussionmentioning

confidence: 85%

A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas

Kayath¹,

Martin²,

Vieira³

et al. 1998

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To investigate immunoexpression of p53 in parathyroid tumors and hyperplasias and correlate it with the histopathological diagnosis and severity of hyperparathyroidism. Design: A total of 102 parathyroid tissues from archival paraffin-embedded specimens or obtained at surgery between 1988 and 1997 from 65 consecutive individuals with hyperparathyroidism were studied. Methods: p53 immunoexpression, gland mass, preoperative serum calcium and intact parathyroid hormone (PTH) were analyzed; 14 normal parathyroid glands were used as controls. Results: The histopathological findings were: adenomas (n=28), primary hyperplasias (n=12), secondary nodular and diffuse hyperplasias (patients with uremia, n=57), carcinomas (n=4) and carcinomatous metastatic tissue (n=1). Nuclear p53 was detected in 36% of the adenomas, 42% of the primary hyperplastic glands, 72% of the diffuse hyperplasias, 44% of nodular hyperplasias and 40% of the carcinomatous tissues, and was absent from normal glands. p53 expression was significantly more frequent in diffuse hyperplasias than in adenomas (P=0·037). Serum ionized calcium tended to be higher in p53-positive glands in all histopathological groups; however, the difference was only significant in nodular hyperplasias (P=0·018). The same trend was observed for serum intact PTH levels of adenomas and nodular hyperplastic glands. Gland mass was not significantly different according to p53 staining. Conclusions: p53 immunoexpression was not useful in differentiating between the histopathological parathyroid subgroups. p53 immunodetection was particularly frequent in secondary hyperplastic glands of uremic patients. Our study suggests that p53, whether wild-type or mutant, is regulated in parathyroid tumors and hyperplasias. Changes in wild-type p53 may be part of a cellular response to a hyperproliferative condition.

show abstract

“…Unlike many studies, we also took into account the intensity of immunoreactivity for both p53 and pRb, consistent with other studies that have evaluated their expression abnormalities in organ systems other than bladder cancer. [32][33][34][35][36][37][38] The final composite score comprised both extent and intensity components. We believe that this composite scoring system, together with the assignment of a narrower range for p53 overexpression (score 4-6) and pRb underexpression (score 0-2), possibly allows a better definition of abnormalities of p53 and pRb expression, thus providing more rigor in examining the correlation between these abnormalities and clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha

Esuvaranathan

Chiong

Thamboo

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUNDNuclear p53 and retinoblastoma protein (pRb) were reported to be poor prognostic indicators for transitional cell carcinoma of the bladder. The authors sought to determine the prognostic value of nuclear p53 and pRb in superficial bladder transitional cell carcinoma patients who were treated with intravesical bacille Calmette‐Guerin (BCG) or BCG with interferon‐alpha (IFN‐α).METHODSA prospective histological review was performed for 80 superficial bladder transitional cell carcinoma patients who underwent postresection intravesical regimes of BCG (81mg, n = 33 or 27 mg, n = 20) or BCG (27 mg) with IFN‐α (n = 27), and followed for a mean of 4.5 years. Hematoxylin and eosin (H & E) and immunoperoxidase staining were performed on tissue sections. Nuclear p53 and pRb immunoreactivity were assessed semiquantitatively, by using a combination of staining extent and intensity, to categorize overexpression or underexpression. Data were analyzed by using chi‐square analysis, multiple logistic regression, and Kaplan‐Meier curves.RESULTSpRb expression was not associated with patient outcome after BCG‐alone therapy, but pRb underexpression was significantly associated with BCG nonresponse and tumor recurrence (P = .047) after BCG and IFN‐α (BCG + IFN‐α) therapy. Low‐grade tumors were associated with pRb overexpression, with or without nuclear p53 underexpression (P = .019; P = .043, respectively). p53 expression alone or in combination with pRb expression had no significant relation with tumor response to BCG alone or BCG + IFN‐α with respect to recurrence, progression, or cancer‐specific death.CONCLUSIONSNuclear pRb underexpression may be predictive of nonresponse and cancer recurrence after intravesical BCG + IFN‐α therapy. Nuclear p53 expression or its combination with pRb expression is not associated with post‐BCG clinical outcome, so p53 expression or p53 with pRb expression should not be used to influence decisions concerning BCG‐alone or BCG + IFN‐α therapy. Cancer 2007. © 2007 American Cancer Society.

show abstract

p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin

Cited by 57 publications

References 18 publications

Aberrant Expression Patterns of Histone H3 mRNA, p53, Cyclin D1, and Cyclin B1 in Oral Neoplastic Epithelial Lesions

Aberrant Expression Patterns of Histone H3 mRNA, p53, Cyclin D1, and Cyclin B1 in Oral Neoplastic Epithelial Lesions

A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas

Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alpha

Contact Info

Product

Resources

About